PPARδ agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
==== MeSH D06.472.931 – thyroid hormones ==== MeSH D06.472.931.103 – dextrothyroxine MeSH D06.472.931.208 – diiodotyrosine MeSH D06.472.931.388 – monoiodotyrosine MeSH D06.472.931.669 – thyroid gland, desiccated MeSH D06.472.931.740 – thyronines MeSH D06.472.931.740.180 – diiodothyronines MeSH D06.472.931.740.385 – triiodothyronine MeSH D06.472.931.740.590 – triiodothyronine, reverse MeSH D06.472.931.812 – thyroxine
== Pharmacology: Pharmacodynamics/Mechanism of Action(MOA) == Synthetic cannabinoids act as Synthetic Cannabinoid Receptor Agonists (SCRA) by binding to cannabinoid receptors CB1 and CB2 . Its binding towards CB1 receptor will lead to receptor phosphorylation that recruits β-arrestin 1 and β-arrestin 2, resulting in a loss of responsiveness and internalization (endocytosis of molecules by the cell). Stimulation of CB1 receptor causes the dissociation of the βγ subunits of pertussis toxin-sensitive G proteins (Gi /Go) from the α subunit (Giα) which then contributes to acute inhibition of synaptic neurotransmitter release. β-arrestin can also stimulate the mitogen-activated protein kinase, thus inducing additional cellular effects. Synthetic cannabinoids can also bind to receptors other than CB1 and CB2 to activate inotropic transient receptor potential channels for cell membrane depolarization and Ca2+ influx.
== Mass spectrometry == Collisional excitation in mass spectrometry is the process where an ion collides with an atom or molecule and leads to an increase in the internal energy of the ion. Molecular ions are accelerated to high kinetic energy and then collide with neutral gas molecules (e.g. helium, nitrogen or argon). In the collision some of the kinetic energy is converted into internal energy which results in fragmentation in a process known as collision-induced dissociation.
Bromelain, a concentrate of proteolytic enzymes from the pineapple plant, is used in medicine. It is approved in the European Union for the debridement (removal of eschar, that is dead and damaged tissue) of severe burn wounds under the brand name Nexobrid. It was developed by MediWound. The medicine has been granted orphan drug status by the European Medicines Agency (EMA). In other contexts, bromelain has been researched for possible anti-inflammatory effects in treating a range of conditions or diseases, but results of these studies are mixed and regarded as preliminary. In December 2022, anacaulase-bcdb (Nexobrid) was approved for medical use in the United States.
being positive) when fully (or highly) ionized. Theoretically, this happens for the following 12 nuclides: 148Eu, 163Dy, 193Ir, 194Au, 202Tl, 205Tl, 213Po, 215At, 222Rn, 244Pu, 243Am, and 246Bk. The following table lists theoretically-possible bound-state β− transitions that are impossible for neutral atoms. The
Sources: en.wikipedia.org
== Classification == Vertebral artery dissection is one of the two types of cervical artery dissection. The other type, carotid artery dissection, involves the carotid arteries. Vertebral artery dissection is further classified as being either traumatic (caused by mechanical trauma to the neck) or spontaneous, and it may also be classified by the part of the artery involved: extracranial (the part outside the skull) and intracranial (the part inside the skull).
Liver or kidney failure – Lorazepam may be safer than most benzodiazepines in people with impaired liver function. Like oxazepam, it does not require liver oxidation, but only liver glucuronidation into lorazepam-glucuronide. Therefore, impaired liver function is unlikely to result in lorazepam accumulation to an extent causing adverse reactions. Similarly kidney disease has minimal effects on lorazepam levels. Drug and alcohol dependence – The risk of abuse of lorazepam is increased in dependent people. Comorbid psychiatric disorders also increase the risk of dependence and paradoxical adverse effects.
After Santiesteban Prats informed Viñas Alonso about the conversation, the Grand Master and the Grand Commander disagreed on where the money should be kept, but it did stay in the Grand Master's office. According to a report by Urquía Carreño, on January 5, 2024, at the offices of the National Masonic Temple, Grand Treasurer Airán Cervera pulled Urquía Carreño aside, and asked him if they could discuss something in private. They went up to the roof, where Airán Cervera told Urquía Carreño that the safe was gone, probably stolen. Urquía Carreño, according to his report, kept this information to himself. At 10:15am on January 9, 2024, the Director of Llansó called Grand Commander Viñas Alonso to inform him that they were in the midst of a food shortage. The two men decided to withdraw 1,000 dollars from the vaults of the Grand Lodge to buy food for the residents. At around noon, Viñas Alonso called Urquía Carreño to inform him that Viñas Alonso would be joined by the Treasurer of the Board of Trustees, Ernesto Valdés García, the Secretary of the Board of Trustees, Frank E. Quevedo Martín, and the Director of the retirement home, Raúl Acosta to come to the vault and withdraw 1,000 dollars. After being informed of the situation, Grand Master Urquía Carreño said that the elevator in his office was broken, and that Urquía Carreño would bring the money to the offices of the Supreme Council. Grand Commander Viñas Alonso refused, citing the rules. Urquía Carreño said that he understood, and would call later to tell Viñas Alonso what time they could come by the office.
They often show dilated endoplasmic reticulum, numerous vesicular bodies, and a lack of microtubular structure in transmission electron microscopy study. Therefore, interpretation of these observations would be that despite high protein production and protein turnover in diabetic ulcer fibroblasts, vesicles containing secretory proteins could not travel along the microtubules to release the products outside. Fibroblasts from diabetic ulcer exhibit proliferative impairment that probably contributes to a decreased production of extracellular matrix proteins and delayed wound contraction and impaired wound healing. Increased matrix metalloproteinases (MMP) activity For a wound to heal, extracellular matrix not only needs to be laid down but also must be able to undergo degradation and remodeling to form a mature tissue with appropriate tensile strength. Proteases, namely matrix metalloproteinases are known to degrade almost all the extracellular matrix components. They are known to be involved in fibroblast and keratinocyte migration, tissue reorganization, inflammation, and remodeling of the wounded tissue. Due to persistently high concentrations of pro-inflammatory cytokines in diabetic ulcers, MMP activity is known to increase by 30 fold when compared to acute wound healing. MMP-2 and MMP-9 show sustained overexpression in chronic non-healing diabetic ulcers. Balance in the MMP activity is usually achieved by tissue inhibitor of metalloproteinases (TIMP).
=== Remote vehicle disabling systems === Remote vehicle disabling systems provide users at remote locations the ability to prevent an engine from starting, prevent movement of a vehicle, and to stop or slow an operating vehicle. Remote disabling allows a dispatcher or other authorized personnel to gradually decelerate a vehicle by downshifting, limiting the throttle capability, or bleeding air from the braking system from a remote location. Some of these systems provide advance notification to the driver that the vehicle disabling is about to occur. After stopping a vehicle, some systems will lock the vehicle's brakes or will not allow the vehicle's engine to be restarted within a certain time-frame. Remote disabling systems can also be integrated into a remote panic and emergency notification system. In an emergency, a driver can send an emergency alert by pressing a panic button on the dashboard, or by using a key-fob panic button if the driver is within close proximity of the truck. Then, the carrier or other approved organization can be remotely alerted to allow a dispatcher or other authorized personnel to evaluate the situation, communicate with the driver, and/or potentially disable the vehicle.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.